ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Oncology

Macomics and IFOM Announce Collaboration on Macrophage Research in Oncology

Monday, May 13, 2024

Macomics Ltd, a leader in macrophage drug discovery, has announced a significant scientific collaboration with Prof. Massimiliano Pagani from IFOM, the AIRC Institute of Molecular Oncology, a prominent research institute in Italy focused on Cancer Research.

IFOM concentrates on studying cancer formation and development at the molecular level. Prof. Pagani's laboratory is at the forefront of research on Regulatory T cells in the tumor microenvironment. This collaboration involves Macomics working with Dr. Francesca Simoncello in Prof. Pagani’s lab to merge their expertise, particularly in the use of ex vivo tumoroids and T cell biology, with Macomics' macrophage proficiency. The goal is to explore new modes of action for macrophage-targeted therapies.

Macomics is exploiting macrophage-targeted approaches to develop medicines for diseases with high unmet medical needs. Their ENIGMAC macrophage drug discovery platform enables access to disease-specific macrophage targets by integrating human datasets, human macrophage cell models, and macrophage genome editing capabilities.

Under this collaboration, both parties will investigate the potential use of ex vivo tumoroid models developed by the Pagani lab to characterize macrophage-targeted therapies.

Macomics, said, "We are delighted to collaborate with one of the leading centers of excellence in T-cell biology. This collaboration will allow us to optimize the design of our therapies by using patient-derived organoids, which better mimic the complexity of the human tumor microenvironment."

IFOM and Professor of Molecular Biology at the University of Milan, stated, "A key goal for IFOM is the rapid transfer of scientific results from bench to bedside. This collaboration fits that goal, bringing together experts across disciplines to accelerate the discovery of new therapies."

Macomics, said, "This collaboration brings together technology, assays, and therapeutic strategies to address the challenge of macrophage drug discovery. We are advancing programs in our pipeline towards clinical studies, aiming to bring new therapies to cancer patients."

 

Source: globenewswire.com

magazine-slider-img
Oliver Healthcare Packaging Pharmaceutical SolutionsThermoFisher - Mastering API production at every scaleFuture Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing Pharma
cytiva